EGFR and non-small cell lung carcinoma: Furthermore, Osimertinib is also recommended as an adjuvant therapy option for eligible patients with completely resected stage IB to IIIA NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or L858R mutations who have previously received adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy [13].